Method for preparing ginsenodie composition having enhanced whole-body exposure, ginsenoside composition prepared thereby, and functional food composition comprising same
The fermentation method enhances the bioavailability of ginsenosides by increasing their plasma concentrations, addressing the limitations of existing methods and providing improved therapeutic benefits.
Patent Information
- Application Number
- PCT/KR2023/019998
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-11
- Filing Date
- 2023-12-06
- Publication Date
- 2024-11-14
AI Technical Summary
Current methods for producing ginsenoside compositions do not effectively enhance systemic exposure after ingestion, limiting the bioavailability and therapeutic effects of ginsenosides in the human body.
A method involving fermentation of a red ginseng-derived extract in the presence of Lactobacillus spp. and enzymes, which increases the content and bioavailability of specific ginsenosides like Rh2, F2, CY, PPD, and CK, thereby enhancing their systemic exposure.
The method significantly increases the maximum plasma concentration of these ginsenosides, improving their bioavailability and enabling enhanced therapeutic effects such as reducing skin inflammation, hair loss, increasing procollagen synthesis, preventing skin aging, and inhibiting adipocyte differentiation.
Smart Images

Figure KR2023019998_14112024_PF_FP_ABST
Abstract
Description
Method for producing a ginsenoside composition with enhanced whole-body exposure, a ginsenoside composition produced thereby, and a functional food composition comprising the same
[0001] The present invention relates to a method for producing a ginsenoside composition with enhanced whole-body exposure, a ginsenoside composition produced thereby, and a functional food composition comprising the same.
[0002] Ginseng has long been a popular medicinal food in Eastern and Western countries. Ginsenosides, the main active ingredients in ginseng, possess various beneficial effects. Ginsenosides are structurally divided into protopanaxadiol (PPD) and protopanaxatriol (PPT) types, depending on the hydroxyl group or hydrogen at C6. PPD-type ginsenosides with a hydrogen at C6 include Rc, Rb1, Rb2, Rd, Rh2, F2, compound Y (CY), Rg3, compound K (CK), and PPD. PPT-type ginsenosides with a hydroxyl group at C6 include Re, Rg1, Rf, Rh1, and PPT.
[0003] One object of the present invention is to provide a method for producing a ginsenoside composition in which systemic exposure of ginsenoside is enhanced after ingestion of the composition.
[0004] Another object of the present invention is to provide a ginsenoside composition having enhanced systemic exposure, manufactured through the above method.
[0005] Another object of the present invention is to provide a functional food composition exhibiting functionality, including the above ginsenoside composition.
[0006] In one aspect, the present invention provides a method for producing a ginsenoside composition with enhanced systemic exposure, comprising a fermentation step of fermenting a composition containing a red ginseng-derived extract in the presence of Lactobacillus spp. and an enzyme.
[0007] In one embodiment, the composition may enhance the maximum plasma concentration of one or more substances selected from the group consisting of Rh2, F2, CY, PPD, PPT and CK after ingestion.
[0008] In one embodiment, the content of PPD ginsenosides including Rc, Rb1, Rb2, Rd, Rh2, F2, CY, Rg3, CK and PPD in the composition after the fermentation step may increase by about 40% or more.
[0009] In one embodiment, the content of PPD ginsenosides including Rc, Rb1, Rb2, Rd, Rh2, F2, CY, Rg3, CK and PPD in the composition after the fermentation step may increase by about 40 to 60%.
[0010] In one embodiment, a ginsenoside composition prepared by the method for preparing a ginsenoside composition with enhanced systemic exposure may include about 2 mg / g or more of F2.
[0011] In one embodiment, the ginsenoside composition prepared by the method for preparing a ginsenoside composition with enhanced systemic exposure may comprise about 2 to 3 mg / g of F2.
[0012] In one embodiment, a ginsenoside composition prepared by the method for preparing a ginsenoside composition with enhanced systemic exposure may include about 2.5 mg / g or more of CY.
[0013] In one embodiment, the ginsenoside composition prepared by the method for preparing a ginsenoside composition with enhanced systemic exposure may include about 2.5 to 3.5 mg / g of CY.
[0014] In one embodiment, the content of PPT-based ginsenosides including Rg1 and PPT in the composition after the fermentation step may be reduced by about 5 to 10%.
[0015] In one embodiment, the method for preparing the ginsenoside composition with enhanced systemic exposure can enhance the maximum plasma concentration of one or more substances selected from the group consisting of Rh2, F2, CY, PPD, PPT, and CK about 3 to 12 hours after ingestion of the composition.
[0016] In one embodiment, the method for producing a ginsenoside composition with enhanced systemic exposure can enhance the sum of maximum plasma concentrations of Rh2, F2, CY, PPD and PPT by about 10 times or more after ingestion of the composition.
[0017] In one embodiment, the method for producing a ginsenoside composition with enhanced systemic exposure can enhance the sum of maximum plasma concentrations of Rh2, F2, CY, PPD and PPT by about 10 to 15 times after ingestion of the composition.
[0018] In one embodiment, the method for preparing the ginsenoside composition with enhanced systemic exposure can enhance the maximum plasma concentration of CK by about 60 times or more after ingestion of the composition.
[0019] In one embodiment, the method for preparing the ginsenoside composition with enhanced systemic exposure can enhance the maximum plasma concentration of CK by about 60 to 70 times after ingestion of the composition.
[0020] In another aspect, the present invention provides a ginsenoside composition comprising about 15 mg / g or more of PPD-based ginsenosides including Rc, Rb1, Rb2, Rd, Rh2, F2, CY, Rg3, CK and PPD, and about 1 mg / g or more of PPT-based ginsenosides including Rg1 and PPT.
[0021] In one embodiment, the ginsenoside composition may include about 15 to 20 mg / g of PPD-based ginsenosides including Rc, Rb1, Rb2, Rd, Rh2, F2, CY, Rg3, CK, and PPD, and about 1 to 1.5 mg / g of PPT-based ginsenosides including Rg1 and PPT.
[0022] In one embodiment, the ginsenoside composition may comprise about 2 mg / g or more of F2.
[0023] In one embodiment, the ginsenoside composition may comprise about 2 to 3 mg / g of F2.
[0024] In one embodiment, the ginsenoside composition may comprise about 2.5 mg / g or more of CY.
[0025] In one embodiment, the ginsenoside composition may comprise about 2.5 to 3.5 mg / g of CY.
[0026] In one embodiment, the ginsenoside composition may comprise about 12 mg / g or more of CK.
[0027] In one embodiment, the ginsenoside composition may comprise about 12 to 14 mg / g of CK.
[0028] In one embodiment, the ginsenoside composition can be prepared by the method for preparing a ginsenoside composition with enhanced systemic exposure.
[0029] In another aspect, the present invention provides a functional food composition comprising the above ginsenoside composition.
[0030] In one embodiment, the functional food composition can reduce skin inflammation.
[0031] In one embodiment, the functional food composition can reduce hair loss.
[0032] In one embodiment, the functional food composition can increase procollagen synthesis.
[0033] In one embodiment, the functional food composition can prevent skin aging.
[0034] In one embodiment, the functional food composition can inhibit adipocyte differentiation.
[0035] In one embodiment, the functional food composition can reduce the risk of ischemic brain damage.
[0036] In one embodiment, the functional food composition may have one or more dosage forms selected from the group consisting of tablets, capsules, pills, granules, liquids, powders, flakes, pastes, syrups, gels, jellies, bars, and films.
[0037] The method for producing a ginsenoside composition with enhanced systemic exposure according to an embodiment of the present invention can enhance the efficacy of ginsenoside in the human body by enhancing systemic exposure by allowing components that were not previously detected in the plasma of a consumer to be absorbed into the plasma when consuming a red ginseng-derived extract.
[0038] A ginsenoside composition according to an embodiment of the present invention can have improved systemic exposure by being manufactured by the method for manufacturing a ginsenoside composition with improved systemic exposure.
[0039] The functional food composition according to an embodiment of the present invention can perform improved functions in the human body by including the ginsenoside composition and improved systemic exposure.
[0040] Figure 1 is a flow chart illustrating a method for producing a ginsenoside composition with enhanced systemic exposure according to an embodiment of the present invention.
[0041] Figure 2 shows the time-averaged plasma concentration curves of individual ginsenosides and total ginsenosides in an individual after administration of fermented red ginseng extract and red ginseng extract.
[0042] Figure 3 is a graph showing the pharmacokinetic parameters of individual and total ginsenosides after administration of fermented red ginseng extract and red ginseng extract.
[0043] <Explanation of symbols>
[0044] 100: Method for producing a ginsenoside composition with enhanced whole-body exposure
[0045] Hereinafter, embodiments of the present invention will be described in detail with reference to the attached drawings. The present invention may be modified in various ways and may take various forms. Therefore, specific embodiments are illustrated in the drawings and described in detail in the text. However, this is not intended to limit the present invention to a specific disclosed form, but should be understood to include all modifications, equivalents, and substitutes included in the spirit and technical scope of the present invention. In describing each drawing, similar reference numerals are used to indicate similar components. In the attached drawings, the dimensions of structures are shown larger than actual size to ensure clarity of the present invention.
[0046] The terminology used in this application is only used to describe specific embodiments and is not intended to limit the present invention. The singular expression includes the plural expression unless the context clearly indicates otherwise. In this application, the terms "comprise" or "have" should be understood to indicate the presence of a feature, number, step, operation, component, or combination thereof described in the specification, but do not preclude the possibility of the presence or addition of one or more other features, numbers, steps, operations, components, or combinations thereof.
[0047] Unless otherwise defined, all terms used herein, including technical or scientific terms, have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. Terms defined in commonly used dictionaries should be interpreted as having a meaning consistent with their meaning in the context of the relevant technology, and will not be interpreted in an idealized or overly formal sense unless explicitly defined herein.
[0048] Figure 1 is a flow chart illustrating a method for producing a ginsenoside composition with enhanced systemic exposure according to an embodiment of the present invention.
[0049] Referring to FIG. 1, a method for producing a ginsenoside composition with enhanced whole-body exposure according to an embodiment of the present invention (100) may include a fermentation step (S110) of fermenting a composition containing a red ginseng-derived extract in the presence of Lactobacillus spp. and an enzyme.
[0050] The above fermentation step (S110) is a step of fermenting a composition containing a red ginseng-derived extract to induce chemical changes within the composition. The present invention is at least based on the discovery that, due to the chemical changes within the red ginseng-derived extract induced by the fermentation step (S110), the maximum plasma concentration of specific components(s) is enhanced when the composition containing the red ginseng-derived extract is ingested. In one embodiment, the maximum plasma concentration of one or more substances selected from the group consisting of Rh2, F2, CY, PPD, PPT, and CK can be enhanced after ingestion of the composition.
[0051] In the context of the present specification, maximum plasma concentration or Cmax may refer to the maximum value of the concentration of a specific component(s) in the plasma at a specific point in time among the concentrations of the specific component(s) in the plasma over a certain period of time. Therefore, the maximum plasma concentration of one or more substances selected from the group comprising Rh2, F2, CY, PPD, PPT and CK after ingestion of the composition may refer to the maximum value of the concentration of the component(s) in the plasma at a specific point in time among the concentrations of the component(s) in the plasma observed over any period of time. In one embodiment, the method for producing a ginsenoside composition with enhanced systemic exposure (100) may enhance the maximum plasma concentration of one or more substances selected from the group comprising Rh2, F2, CY, PPD, PPT and CK about 3 to 12 hours after ingestion of the composition.
[0052] As long as the maximum plasma concentration of one or more components increases by the fermentation step (S110), the amount of increase in the maximum plasma concentration of one or more components does not particularly limit the scope of the present invention. In one embodiment, the method for producing a ginsenoside composition with enhanced systemic exposure (100) can improve the sum of the maximum plasma concentrations of Rh2, F2, CY, PPD, and PPT by about 10 times or more after ingestion of the composition. In one embodiment, the method for producing a ginsenoside composition with enhanced systemic exposure (100) can improve the sum of the maximum plasma concentrations of Rh2, F2, CY, PPD, and PPT by about 10 to 15 times after ingestion of the composition. In one embodiment, the method for producing a ginsenoside composition with enhanced systemic exposure (100) can improve the maximum plasma concentration of CK by about 60 times or more after ingestion of the composition. In one embodiment, the method for producing a ginsenoside composition with enhanced systemic exposure (100) can enhance the maximum plasma concentration of CK by about 60 to 70 times after ingestion of the composition.
[0053] In the fermentation step (S110), the chemical change in the red ginseng extract induced by the fermentation step (S110) is not particularly limited as long as it increases the maximum plasma concentration after ingestion of one or more components. In one embodiment, the content of PPD-based ginsenosides including Rc, Rb1, Rb2, Rd, Rh2, F2, CY, Rg3, CK and PPD in the composition after the fermentation step (S110) may increase by about 40% or more. In one embodiment, the content of PPD-based ginsenosides including Rc, Rb1, Rb2, Rd, Rh2, F2, CY, Rg3, CK and PPD in the composition after the fermentation step (S110) may increase by about 40 to 60%. In one embodiment, the ginsenoside composition prepared by the method for preparing a ginsenoside composition with enhanced systemic exposure may include about 2 mg / g or more of F2. In one embodiment, the ginsenoside composition manufactured by the method for manufacturing a ginsenoside composition with enhanced systemic exposure may comprise about 2 to 3 mg / g of F2. In one embodiment, the ginsenoside composition manufactured by the method for manufacturing a ginsenoside composition with enhanced systemic exposure may comprise about 2.5 mg / g or more of CY. In one embodiment, the ginsenoside composition manufactured by the method for manufacturing a ginsenoside composition with enhanced systemic exposure may comprise about 2.5 to 3.5 mg / g of CY. In one embodiment, after the fermentation step (S110), the content of PPT-based ginsenosides including Rg1 and PPT in the composition may decrease by about 5 to 10%.
[0054] A ginsenoside composition according to an embodiment of the present invention may include about 15 mg / g or more of PPD-based ginsenosides including Rc, Rb1, Rb2, Rd, Rh2, F2, CY, Rg3, CK, and PPD, and about 1 mg / g or more of PPT-based ginsenosides including Rg1 and PPT. In one embodiment, the ginsenoside composition may include about 15 to 20 mg / g of PPD-based ginsenosides including Rc, Rb1, Rb2, Rd, Rh2, F2, CY, Rg3, CK, and PPD, and about 1 to 1.5 mg / g of PPT-based ginsenosides including Rg1 and PPT.
[0055] In the context of this specification, PPD ginsenosides may encompass ginsenosides that have a similarity in metabolic pathway and / or functional group to PPD, and non-limiting examples thereof may include Rc, Rb1, Rb2, Rd, Rh2, F2, CY, Rg3, CK, and PPD. In the context of this specification, PPT ginsenosides may encompass ginsenosides that have a similarity in metabolic pathway and / or functional group to PPT, and non-limiting examples thereof may include Rg1 and PPT.
[0056] As long as it has the above content, the content of each specific ginsenoside component in the ginsenoside composition is not particularly limited. In one embodiment, the ginsenoside composition may comprise F2 of about 2 mg / g or more. In one embodiment, the ginsenoside composition may comprise F2 of about 2 to 3 mg / g. In one embodiment, the ginsenoside composition may comprise CY of about 2.5 mg / g or more. In one embodiment, the ginsenoside composition may comprise CY of about 2.5 to 3.5 mg / g. In one embodiment, the ginsenoside composition may comprise CK of about 12 mg / g or more. In one embodiment, the ginsenoside composition may comprise CK of about 12 to 14 mg / g.
[0057] The description of the ginsenoside composition according to the embodiment of the present invention above can be applied identically or similarly to the same or similar configuration or terminology in the description of the method for producing a ginsenoside composition with enhanced systemic exposure according to the embodiment of the present invention described above. In addition, the method for producing a ginsenoside composition with enhanced systemic exposure according to the embodiment of the present invention described above can derive the ginsenoside composition according to the embodiment of the present invention or provide a method capable of deriving the ginsenoside composition. In one embodiment, the ginsenoside composition can be produced by the method for producing a ginsenoside composition with enhanced systemic exposure.
[0058] Meanwhile, a functional food composition according to an embodiment of the present invention may include the ginsenoside composition. In the context of this specification, a functional food composition may encompass any food that can be consumed orally and that participates in the body's metabolism to exhibit, enhance, or weaken one or more functions. Therefore, the functions of a functional food composition according to an embodiment of the present invention are not particularly limited.
[0059] The description of the functional food composition according to the embodiment of the present invention above can be applied to the same or similar structures or terms in the description of the method for producing a ginsenoside composition with enhanced systemic exposure according to the embodiment of the present invention described above and / or the description of the ginsenoside composition according to the embodiment of the present invention described above. Accordingly, the function of the functional food composition according to the embodiment of the present invention may include, but is not necessarily limited to, a function known to have or possessed by one or more ingredients mentioned in the method for producing a ginsenoside composition with enhanced systemic exposure according to the embodiment of the present invention described above and / or the ginsenoside composition according to the embodiment of the present invention. In one embodiment, the functional food composition can reduce skin inflammation. In one embodiment, the functional food composition can reduce hair loss. In one embodiment, the functional food composition can increase procollagen synthesis. In one embodiment, the functional food composition can prevent skin aging. In one embodiment, the functional food composition can inhibit adipocyte differentiation. In one embodiment, the functional food composition can reduce the risk of ischemic brain damage.
[0060] In one embodiment, the functional food composition may have one or more dosage forms selected from the group consisting of tablets, capsules, pills, granules, liquids, powders, flakes, pastes, syrups, gels, jellies, bars, and films.
[0061] Hereinafter, embodiments of the present invention will be described in detail. However, the embodiments described below are merely some embodiments of the present invention, and the scope of the present invention is not limited to the embodiments described below.
[0062] ingredient
[0063] Both fermented red ginseng (FRG) and red ginseng (RG) extracts were provided by the Central Research Center of Ilhwa (Guri-si, South Korea).
[0064] Preparation of extract
[0065] Dried RG (1 kg) was extracted with 10 L of ethanol and concentrated using a vacuum concentrator. FRG extract was prepared by fermenting RG with enzymes and Lactobacillus spp.
[0066] Ginsenoside content was analyzed using HPLC (Waters Corporation, 34 Maple Street, Milford, MA 01757, USA) equipped with a Waters Atlantis C18 column (4.5 × 250 mm). The mobile phases were water (A) and acetonitrile (B). The injection volume was 10 μL, and the gradient was as follows: 0–5 min, 20% B; 5–20 min, 23% B; 20–25 min, 30% B; 25–30 min, 40% B; 30–35 min, 50% B; 35–60 min, 85% B. The flow rate was 1 mL / min, and the column oven temperature was 40°C. The component contents of the RG extract and FRG extract are shown in the table below.
[0067] GinsenosidePPD-TypePPT-TypeRcRb1Rb2RdRh2F2CYRg3CKPPDRg1PPTFRG (mg / g)000.13002.243.02012.69001.15RG (mg / g)2.663.161.881.570.2100.142.09001.160.07
[0068] Study design
[0069] This study was designed as a randomized, open-label, single-dose, two-sequence, two-period crossover study with a 2-week washout period to compare the pharmacokinetic parameters of ginsenosides in RG and FRG. All subjects were screened for enrollment in the study, and the enrolled subjects were randomly assigned to one of two sequence groups, sequence 1 and sequence 2. Subjects in sequence group 1 received 6 g of FRG extract in 200 mL of water as the first dose and 6 g of RG extract in 200 mL of water as the second dose, followed by a 2-week washout period. Subjects in sequence group 2 received 6 g of RG extract in 200 mL of water in the first period, and then 6 g of FRG extract in 200 mL of water in the second period after the same washout period. During each period, subjects in groups 1 and 2 were admitted to the experimental site at 5:00 PM on the day before FRG or RG administration. They received a standardized dinner and fasting diet except for water until FRG or RG administration. The next day, FRG or RG was administered according to the assigned sequence at 8:00 AM, and fasting was continued until 1:00 PM. All participants were provided with lunch and dinner by the study staff. They were discharged at 2:00 PM the day after FRG or RG administration and returned to the clinical trial center at 8:00 AM the day after discharge. To assess pharmacokinetic parameters, blood samples (9 mL) were collected serially in heparinized tubes immediately before FRG or RG administration (0 h) and at the following time points after FRG or RG administration: 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 24, and 30 h during hospitalization and 48 h during outpatient visits. Blood samples were placed in heparinized tubes and immediately centrifuged at 3500 × g for 10 min at -4°C. Plasma was stored at -70°C.
[0070] All procedures were performed in accordance with the principles of the Declaration of Helsinki and the Korean Clinical Trial Guidelines.
[0071] Research subject
[0072] Subjects were healthy Korean male volunteers aged 19 to 45 years with a body weight (kg) of 55.0 to 90.0 and a body mass index (BMI, kg / m2) of 18.0 to 27.0.
[0073] Tolerance and safety
[0074] Safety and tolerability were monitored throughout the trial using tests such as adverse events (AEs), blood pressure, body temperature, clinical laboratory tests, and physical examinations. AEs were recorded voluntarily by subjects and assessed by the investigators for intensity, duration, and relationship to dose. Blood pressure and body temperature were measured before dosing and at 2, 4, 8, 14, 24, 30, and 48 hours after FRG or RG administration. Clinical laboratory tests and physical examinations were performed before FRG or RG administration and before discharge.
[0075] bioanalysis
[0076] CY, CK, PPD, PPT, and Rh2 analyses were performed on an Agilent 1200 Series (Agilent Technologies, Santa Clara, CA, USA) or Shimadzu Nexera X2 (Shimadzu, Tokyo, Japan) with ESI and an Applied Biosystems MDS SCIEX API 4000 triple quadrupole mass spectrometer (SCIEX, Framingham, MA, USA) with ESI source in negative ion mode. Data were analyzed and processed using the Analyst 1.6.2 program (SCIEX, Framingham, MA, USA). Rb1 and F2 were analyzed using an Elute UHPLC (Bruker, Billerica, MA, USA) and an EVOQ Elite triple quadrupole mass spectrometer (Bruker, Billerica, MA, USA) with ESI source in positive ion mode. Data were collected and processed using the Analyst 1.6.2 program (SCIEX, Framingham, MA, USA) and a Bruker Daltonic MS Workstation 8.2.1 (Bruker, Billerica, MA, USA). Ginsenoside standards (Rb1, Rh2, and CY) were provided by the Ambo Institute (Daejeon, South Korea). Ginsenoside standards (F2, CK, PPD, and PPT) were provided by Ace Enzyme (Gyeonggi-do, South Korea). Digoxin, diphenhydramine hydrochloride, formic acid, ammonium acetate, and dimethyl sulfoxide were purchased from Sigma Aldrich (Saint Louis, MO, USA). Methanol, acetonitrile, ethyl acetate, and methyl tert-butyl ether were purchased from JT Baker (Philipsburg, NJ, USA). Purified water for HPLC analysis was obtained using an AQUA max® from Younglin Water Purification Systems (Gyeonggi-do, South Korea).The final concentrations of the calibration standards were 0.5, 1, 2, 5, 10, 25, and 50 ng / mL, and the final concentrations of the QC samples were 1.5, 7.5, and 40 ng / mL. The final concentrations of the CK calibration standards were 5, 50, 250, 500, 1000, 1500, and 2500 ng / mL, and the final concentrations of the QC samples were 15, 1200, and 2000 ng / mL. Human plasma samples were removed from the -70°C freezer and thawed at room temperature for bioanalysis. All analytical procedures were performed in accordance with the guidelines for bioanalytical methods of the Korea Ministry of Food and Drug Safety, which include validation processes for selectivity, linearity, accuracy, precision, recovery, matrix effects, and stability.
[0077] Pharmacokinetic and statistical analysis
[0078] Pharmacokinetic parameters for the FRG and RG groups were calculated using noncompartmental analysis methods using PhoenixWinNonlin 8.3 (Certara USA Inc., Princeton, NJ, USA). Maximum drug concentration (Cmax) and time to Cmax (Tmax) were obtained directly from individual data sets, including plasma concentration-time profiles. The area under the concentration-time curve (AUC) was calculated using the linear up / log down trapezoidal rule for noncompartmental analysis. AUClast was calculated from individual data sets of actual concentrations from 0 to the actual time of the last measurable concentration above the LLOQ. The AUC from 0 to 24 h (AUC24) was calculated using individual concentrations, where values below the LLOQ were replaced with 0.
[0079] Demographic characteristics, pharmacokinetic parameters, and safety profiles were described using descriptive statistics. Logarithmically transformed Cmax, AUClast, and AUC24 values were compared between the FRG and RG groups using a linear mixed-effects model. From these mixed-model results, geometric mean ratios (GMRs) with confidence intervals (p-values) for Cmax and AUC in the FRG relative to the RG were obtained by exponentiating the coefficients for the treatment effect. These GMR values were interpreted as the "fold" of Cmax and AUC in the FRG relative to the RG values. Tmax was compared between the FRG and RG using the Wilcoxon signed-rank test.
[0080] Experimental example (result)
[0081] Subject
[0082] Sixteen healthy Korean male volunteers who met the eligibility criteria participated in the study. The demographic characteristics of the 16 subjects, expressed as the mean ± standard deviation, were as follows: age, 25.69 ± 3.88 years; height, 171.71 ± 3.28 cm; weight, 65.31 ± 5.01 kg; and BMI, 22.17 ± 1.85 kg / m2. One subject in the sequence 2 group completed the study. However, data were excluded after period 1 because he consumed RG-related foods during the washout period. Finally, the pharmacokinetic results of this study were analyzed in 15 subjects who received FRG or RG.
[0083] Pharmacokinetic parameters of ginsenosides Rb1, F2, compound Y, Rh2, compound K, PPD, and PPT
[0084] The time-averaged plasma concentration curves of individual ginsenosides and total ginsenosides after FRG and RG administration are shown in Figure 2. The pharmacokinetic parameters of individual and total ginsenosides after FRG and RG administration are shown in Table 2 and Figure 3.
[0085] GinsenosideParameterFRG (n = 15)RG (n = 15)GMR (90% CI)Rb1C max AUC 24 AUC last T max ----2.33 ± 1.6136.46 ± 25.5762.42 ± 48.068.00 (4.00, 14.00)----Rh2C max AUC 24 AUC last T max 32.95 ± 11.88135.40 ± 44.43133.43 ± 42.653.02 (2.00, 6.02)1.77 ± 1.178.97 ± 5.578.35 ± 4.313.00 (2.00, 12.02)20.27 (15.13, 27.17)18.17 (12.4, 26.62)18.47 (12.74, 26.78)0.318F2C max AUC 24 AUC last T max 14.65 ± 3.58142.45 ± 34.27168.07 ± 47.394.03 (3.00, 7.00)--------CYC max AUC 24 AUC last T max 8.38 ± 2.2233.41 ± 9.8232.47 ± 9.443.02 (1.00, 6.02)--------PPDC max AUC 24 AUC last T max 5.65 ± 4.7848.71 ± 41.1592.16 ± 96.4512.01 (5.00, 30.00)1.99 ± 1.6213.94 ± 19.0820.32 ± 25.1127.05 (8.00, 30.03)2.89 (2.04, 4.09)2.95 (1.37, 6.33)4.97 (2.38, 10.34)0.203PPTC max AUC 24 AUC last T max8.92 ± 5.3863.72 ± 42.7783.03 ± 59.446.00 (0.50, 10.00)3.50 ± 2.0034.11 ± 24.6845.74 ± 32.1019.04 (8.00, 30.03)2.56 (1.83, 3.57)1.87 (1.16, 3.01)1.76 (1.17, 2.65)<0.001CKC max AUC 24 AUC last T max 1553.11 ± 394.168707.88 ± 2360.729438.74 ± 2618.683.02 (2.00, 5.00)23.81 ± 12.16158.28 ± 125.29145.43 ± 106.452.00 (1.00, 10.02)69.23 (55.93, 85.69)64.86 (51.12, 82.29)74.53 (59.32, 93.64)0.281Rh2 + F2 + CY + PPD + PPTC max AUC 24 AUC last T max 55.98 ± 14.61422.94 ± 118.64515.26 ± 170.163.02 (2.00, 6.02)5.24 ± 3.0951.74 ± 41.0668.18 ± 53.9212.02 (2.00, 30.03)12.41 (8.83, 17.45)10.8 (7.34, 15.89)10.17 (6.92, 14.96)<0.001
[0086] Cmax (ng / mL), AUC24 (ng·h / mL), and AUClast (ng·h / mL) of all ginsenosides were expressed as mean ± standard deviation, and Tmax (h) was expressed as median (min, max). The Cmax, AUC24, and AUClast of all ginsenosides analyzed, including total ginsenosides, showed significant differences between FRG and RG, except for Rb1, F2, and CY. All comparisons of Cmax, AUC24, and AUClast between FRG and RG were statistically significant at p < 0.001, except for the comparison of AUC24 and AUClast of PPD (p = 0.033, 0.003) or PPT (p = 0.037, 0.029).
[0087] Plasma concentrations of Rb1 in FRG, CY in RG, and F2 in RG could not be assessed because these concentrations were below the LLOQ, except for four consecutive F2 concentrations in one subject. Therefore, Cmax, AUC24, AUClast, and Tmax for Rb1 were calculated only in RG. Similarly, these pharmacokinetic parameters could only be assessed in FRG.
[0088] For Rh2 and CK, the Cmax, AUC24, and AUClast of FRG were higher than those of RG. The Cmax of Rh2 and CK were 20.27- and 69.23-fold higher in FRG than in RG, respectively. The AUC24 values of Rh2 and CK were 18.17- and 64.86-fold higher in FRG than in RG, respectively. The AUClast values of Rh2 and CK were 18.47- and 74.53-fold higher in FRG than in RG, respectively. The median Tmax value of CK in FRG was 1 hour higher than that in RG. The median Tmax value of Rh2 was similar between FRG and RG.
[0089] PPD, PPT, and total ginsenosides (Rh2 + F2 + CY + PPD + PPT) had higher Cmax, AUC24, and AUClast in the FRG than in the RG. The Cmax of PPD, PPT, and total ginsenosides were 2.89-fold, 2.56-fold, and 12.41-fold higher in the FRG than in the RG, respectively. The AUC24 values of PPD, PPT, and total ginsenosides in the FRG were 2.95-fold, 1.87-fold, and 10.8-fold higher than in the RG, respectively. The AUClast values of PPD, PPT, and total ginsenosides were 4.97-fold, 1.76-fold, and 10.17-fold higher in the FRG than in the RG, respectively. The median Tmax of PPD, PPT, and total ginsenosides in the FRG was lower than in the RG.
[0090] Ginsenosides are absorbed and metabolized in the gastrointestinal tract and liver, enter the systemic circulation, and exhibit pharmacological effects such as anticancer and antioxidant effects. To enhance the absorption of ginsenosides into the systemic circulation, the relative amount of downstream compounds among all types of ginsenosides in the ginseng extract must be high. Since the fermentation process of RG, i.e., FRG, increases the relative amount of downstream ginsenosides, consumption of FRG is expected to increase the absorption of these compounds. This expectation was confirmed in the present experimental example, where absorption or exposure to ginsenosides was significantly higher in FRG than in RG. The Cmax and AUC values of ginsenosides after FRG and RG administration were compared to assess the difference in systemic exposure. In particular, systemic exposure to CY, F2, CK, Rh2, PPD, and PPT was higher in FRG than in RG. However, systemic exposure to Rb1 was observed only in RG. This is because Rb1 is converted to downstream ginsenosides during fermentation. In the evaluation of median Tmax values, most ginsenosides in FRG were absorbed faster than those in RG. This result can be interpreted as indicating that the conversion of downstream ginsenosides takes longer in RG, which has a higher content of upstream ginsenosides than FRG. However, the Tmax of Rh2 was similar between FRG and RG, and the Tmax of CK for RG was 1 hour lower than that of FRG. An individual comparison of Tmax for CK showed that the interindividual variability of Tmax for FRG was smaller than that for RG.
[0091] Rb1, the most upstream product of PPD-type ginsenosides, has a high molecular weight (MW) and polarity due to the glucose at C20 of its structure, which may interfere with its absorption in the body. During the fermentation process, Rb1 can be metabolized into downstream ginsenosides with lower MW and lower polarity, namely CY, F2, and Rh2, through enzymatic deglycosylation of glucose. The effect of fermentation was confirmed by comparing the amounts of individual ginsenosides in RG and FRG. Rb1 was contained only in the RG extract and not in the FRG extract. Therefore, the Cmax and AUC of Rb1 could be determined only after administration of the RG extract. These results confirm that Rb1 is metabolized into downstream ginsenosides during the fermentation of the RG extract.
[0092] F2, CY, and Rh2 are produced by deglycosylation of precursor ginsenosides such as Rb1 and Rb2. The content of F2, a metabolite of Rb1 and Rb2, was higher in FRG than in RG, and the Cmax and AUC were also significantly higher in FRG than in RG. Considering that the plasma concentration value above the LLOQ in RG was 4 in only one subject, Rb1 in RG was likely metabolized to F2 or Rg3 by the gastrointestinal microbiome or liver after absorption, and the metabolic conversion to F2 was small, or F2 was rapidly converted to downstream ginsenosides such as CK and PPD. Similarly, FRG contained higher amounts of CY, a metabolite of Rb2, than RG, and systemic exposure to CY was higher in FRG than in RG. All plasma concentrations of CY were below the LLOQ after RG administration. Considering that the CY content of RG is 0.14 mg / g, it is expected that most of the CY of RG is converted into downstream ginsenosides such as CK upon absorption in the body.
[0093] The CY and F2 contents of FRG were 3.02 mg / g and 2.24 mg / g, respectively. However, the systemic exposure of CY was relatively lower in FRG administration than in F2. The Cmax and AUClast of CY were 8.38 ng / mL and 32.47 ng·h / mL, respectively, and the Cmax and AUClast of F2 were 14.65 ng / mL and 168.07 ng·h / mL, respectively. These results confirm that Rb2 is metabolized to F2 to a greater extent than CY, and that CY is rapidly metabolized to CK while CY is absorbed more than F2. Meanwhile, the pharmacokinetic findings of Rh2 between FRG and RG were similar to those of F2. Cmax and AUC were significantly higher in FRG administration than in RG administration. This pharmacokinetic difference was opposite to the content difference between FRG and RG. The Rh2 content was higher in RG than in FRG. These results suggest that upstream ginsenosides, such as F2, in FRG may have been converted to Rh2 primarily by gut microbes or microbes in fermented foods provided during the study. Meanwhile, F2 has a protective effect against skin inflammation by suppressing interleukin (IL)-17A, a key cytokine in skin inflammation, and ROS production in neutrophils. Furthermore, F2 reduces hair loss by inhibiting the expression of TGF-β2-related factors involved in hair loss and disrupts the SCAP-associated apoptosis pathway in vitro and in vivo. CY increases the synthesis of procollagen, a protective factor against skin aging, in vitro. Rh2 inhibits adipocyte differentiation in vitro by suppressing PPAR-α, a key transcription factor in adipocyte differentiation, and reduces ischemic brain damage by inhibiting PGE2 synthesis in LPS-stimulated RAW264.7 cells. Therefore, FRG administration may exhibit the aforementioned beneficial effects on ginsenosides F2, CY, and Rh2 compared to RG administration.
[0094] Among the PPD ginsenosides, CK has less polarity and lower molecular weight than upstream ginsenosides, making it easily absorbed by the human body. CK is mainly produced from F2 and CY through the fermentation process, which is reflected in the difference in CK levels between FRG (12.69 mg / g) and RG (0 mg / g). In addition, the Cmax and AUC of CK were significantly higher after FRG administration than after RG administration. In the case of RG, it is thought that the CK concentration was measured through the metabolic pathway from Rc, Rb1, and Rb2 to CK, although the content of CK is not present in RG. In addition, the Cmax( / g) and AUC( / g) normalized to the amount of FRG in this study were compared with the pharmacokinetic results of a previous study normalized to the FRG dose.
[0095] For example, CK can promote neuronal survival by inducing brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF), which have neuroprotective activity in mice and rats and have beneficial effects on streptozotocin-induced diabetic rats. It can also activate insulin sensitivity through the PI3K / Akt signaling pathway. CK increases heme oxygenase-1 (HO-1) with anti-inflammatory activity in mice, exerts anticancer effects by stimulating caspase-3, which induces apoptosis in vitro, and inhibits cellular DNA synthesis, leading to cell cycle arrest in the G1 phase. Therefore, regular administration of FRG, as used in this experimental example, is expected to maximize the pharmacological effects of CK.
[0096] PPD and PPT are the final products of PPD-type and PPT-type ginsenosides, respectively. Furthermore, the Cmax and AUC of PPD and PPT were both higher in the FRG group than in the RG group. The median Tmax values of PPD and PPT were smaller in the FRG group than in the RG group. In particular, the Cmax, AUC24, and AUClast of PPD were approximately 3-fold, 3-fold, and 5-fold higher, respectively, in the FRG group than in the RG group. These results indicate that the PPT content was higher in the FRG group than in the RG group, and that more upstream ginsenosides were metabolized to PPD after FRG administration compared to the RG group. However, the PPD content was absent in both the FRG and RG groups.
[0097] Although the present invention has been described above with reference to preferred embodiments thereof, it will be understood by those skilled in the art that various modifications and changes may be made to the present invention without departing from the spirit and scope of the present invention as set forth in the claims below.
Claims
1. A fermentation step comprising fermenting a composition containing a red ginseng-derived extract in the presence of Lactobacillus spp. and an enzyme, After ingestion of the above composition, the maximum plasma concentration of one or more substances selected from the group consisting of Rh2, F2, CY, PPD, PPT and CK is enhanced. A method for producing a ginsenoside composition with enhanced whole-body exposure.
2. In paragraph 1, After the above fermentation step, the content of PPD ginsenosides including Rc, Rb1, Rb2, Rd, Rh2, F2, CY, Rg3, CK and PPD in the composition increases by 40% or more. A method for producing a ginsenoside composition with enhanced whole-body exposure.
3. In paragraph 2, The ginsenoside composition manufactured by the method for manufacturing the ginsenoside composition with enhanced whole body exposure comprises F2 of 2 mg / g or more. A method for producing a ginsenoside composition with enhanced whole-body exposure.
4. In paragraph 2, The ginsenoside composition manufactured by the method for manufacturing the ginsenoside composition with enhanced whole body exposure comprises CY of 2.5 mg / g or more. A method for producing a ginsenoside composition with enhanced whole-body exposure.
5. In paragraph 1, After the fermentation step, the content of PPT ginsenosides including Rg1 and PPT in the composition is reduced by 5% or more. A method for producing a ginsenoside composition with enhanced whole-body exposure.
6. In paragraph 1, The method for producing a ginsenoside composition with enhanced systemic exposure described above improves the maximum plasma concentration of one or more substances selected from the group consisting of Rh2, F2, CY, PPD, PPT and CK 3 to 12 hours after ingestion of the composition. A method for producing a ginsenoside composition with enhanced whole-body exposure.
7. In paragraph 1, The method for producing the ginsenoside composition with enhanced whole body exposure improves the sum of the maximum plasma concentrations of Rh2, F2, CY, PPD and PPT by more than 10 times after ingestion of the composition. A method for producing a ginsenoside composition with enhanced whole-body exposure.
8. In paragraph 1, The method for producing the ginsenoside composition with enhanced systemic exposure described above improves the maximum plasma concentration of CK by more than 60 times after ingestion of the composition. A method for producing a ginsenoside composition with enhanced whole-body exposure.
9. Contains 15 mg / g or more of PPD ginsenosides including Rc, Rb1, Rb2, Rd, Rh2, F2, CY, Rg3, CK and PPD, Containing 1 mg / g or more of PPT ginsenosides including Rg1 and PPT, A ginsenoside composition with enhanced systemic exposure.
10. In paragraph 9, The above ginsenoside composition comprises F2 of 2 mg / g or more, A ginsenoside composition with enhanced systemic exposure.
11. In paragraph 9, The above ginsenoside composition comprises CY of 2.5 mg / g or more, A ginsenoside composition with enhanced systemic exposure.
12. In paragraph 9, The above ginsenoside composition comprises CK of 12 mg / g or more. A ginsenoside composition with enhanced systemic exposure.
13. In any one of paragraphs 9 to 12, The above ginsenoside composition is manufactured by the method for manufacturing a ginsenoside composition with enhanced systemic exposure according to claim 1. A ginsenoside composition with enhanced systemic exposure.
14. A composition comprising a ginsenoside composition with enhanced systemic exposure according to any one of claims 9 to 12. Functional food composition.
15. In paragraph 14, The above functional food composition reduces skin inflammation, Functional food composition.
16. In paragraph 14, The above functional food composition reduces hair loss, Functional food composition.
17. In paragraph 14, The above functional food composition increases procollagen synthesis, Functional food composition.
18. In paragraph 14, The above functional food composition inhibits adipocyte differentiation. Functional food composition.
19. In paragraph 14, The functional food composition has at least one formulation selected from the group consisting of tablets, capsules, pills, granules, liquids, powders, flakes, pastes, syrups, gels, jellies, bars, and films. Functional food composition.
Citation Information
Patent Citations
A composition comprising fermentation extract of red ginseng for promoting hair growth and inhibition hair loss
KR101741483B1
Method for manufacturing whole red ginseng liquid for maximizing digestion absorption of active ingredient of red ginseng through biochemical fermentation and enzyme dissolution
KR1020170082286A
Porous inorganic particle, and composite filler, product using the same
KR1020230138762A
The manufacturing method of fermented red ginseng extracts enhanced with ginsenoside compound K, Rd and Rd3 using β-glucosidase and lactic acid bacteria
KR102259131B1
